Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

This study is testing a new combination chemotherapy regimen called IB-FOLFIRI for people with metastatic colorectal cancer that has a specific genetic mutation called BRAF V600E. This mutation makes standard treatments less effective, and researchers are looking for better options. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed metastatic colorectal cancer with a BRAF V600E mutation (confirmed by tissue or blood test) - Your cancer has progressed after at least one prior treatment (oxaliplatin-based chemotherapy) - Irinotecan has not previously failed in your treatment - You have at least one measurable tumor - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have received irinotecan before and your cancer progressed on it - You have significant organ dysfunction or serious health conditions that make chemotherapy unsafe Talk to your doctor to see if this trial is right for you.